May 4, 2023
Contact:
Charles Ben-Cofie
Senior Content Manager, Notch Communications
+44 (0) 161-457-7230
charles.ben-cofie@notchcommunications.co.uk
Veranova Appoints Mike Riley as Chief Executive Officer
WAYNE, PA – Veranova announced today the appointment of Mike Riley as the company’s Chief Executive Officer. In this capacity, Mr. Riley will assume responsibility for Veranova’s global business, effective Monday, May 8, and will report directly to the Veranova Board of Directors (the Board).
Over the past two years, Niek Stapel has led the business through its sale from Johnson Matthey (LSE:JMAT) to Altaris, LLC (collectively with its affiliates, “Altaris”) and subsequent re-branding and launch as Veranova. Altaris and the Board thank Mr. Stapel for his service and contributions to Veranova through a period of significant change and transition, and wish him well in his future endeavors.
Mike Riley
Mr. Riley is a seasoned executive, with over 25 years of professional experience, of which nearly 19 years have been spent in the pharmaceutical contract development and manufacturing operations (CDMO) industry building, leading, and growing global businesses. Most recently, Mr. Riley served at Catalent, Inc. as President of the Biotherapeutics business, a multi-site business unit with 6,500 employees and revenue over $1B.
Mr. Riley’s extensive knowledge of the life-sciences and CDMO industry, experience delivering innovative solutions to the pharmaceutical industry, and his proven track record of growing businesses make him ideally suited to lead Veranova as it prepares for its next phase of growth. The Board welcomes Mr.Riley and is excited about working with him to continue to build Veranova into a world-class CDMO.
Veranova announced today the appointment of Mike Riley as the company’s Chief Executive Officer. In this capacity, Mr. Riley will assume responsibility for Veranova’s global business, effective Monday, May 8, and will report directly to the Veranova Board of Directors (the Board).
Over the past two years, Niek Stapel has led the business through its sale from Johnson Matthey (LSE:JMAT) to Altaris, LLC (collectively with its affiliates, “Altaris”) and subsequent re-branding and launch as Veranova. Altaris and the Board thank Mr. Stapel for his service and contributions to Veranova through a period of significant change and transition, and wish him well in his future endeavors.
Mr. Riley is a seasoned executive, with over 25 years of professional experience, of which nearly 19 years have been spent in the pharmaceutical contract development and manufacturing operations (CDMO) industry building, leading, and growing global businesses. Most recently, Mr. Riley served at Catalent, Inc. as President of the Biotherapeutics business, a multi-site business unit with 6,500 employees and revenue over $1B.
Mr. Riley’s extensive knowledge of the life-sciences and CDMO industry, experience delivering innovative solutions to the pharmaceutical industry, and his proven track record of growing businesses make him ideally suited to lead Veranova as it prepares for its next phase of growth. The Board welcomes Mr.Riley and is excited about working with him to continue to build Veranova into a world-class CDMO.
About Veranova
At Veranova, our Custom Pharma Solutions offering provides a full range of dedicated drug development, scale-up and manufacturing services from pre-clinical and toxicological studies to development and commercial manufacturing. Our expert teams can solve the most challenging chemistry and scale-up problems, bringing a unique blend of deep R&D knowledge and specialist capabilities, combined with large-scale global capabilities, to accelerate your innovation. To learn more, visit https://veranova.com/.
Categorized in: Members